

YOU ARE INVITED TO ATTEND



FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.

- FASENRA is not indicated for treatment of other eosinophilic conditions
- FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus

EM_Event_vod__c.Topic_vod__r.Approved_Name_AZ__c

EM_Event_vod__c.Formatted_date_AZ_US__c

**EM_Event_vod__c.Invitation_Time_AZ_US__c – EM_Event_vod__c.
Invitation_End_Time_AZ_US__c**

EM_Event_vod__c.Invitation_Time_Zone_AZ_US__c

LOCATION

EM_Event_vod__c.Location_Name_AZ__c

EM_Event_vod__c.Location_Address_vod__c

EM_Event_vod__c.Location_City_AZ__c, EM_Event_vod__c.Location_State_AZ__c

EM_Event_vod__c.Location_Zip_AZ__c

PRESENTED BY

**EM_Event_vod__c.Speaker_First_Name_AZ_US__c EM_Event_vod__c.
Speaker_Last_Name_AZ_US__c**

EM_Event_vod__c.Speaker_Title_AZ_US__c

EM_Event_vod__c.Speaker_Institution_AZ_US__c

RSVP IS REQUIRED BY: 2024-06-27 00:00:00

To find out more information or to register, please contact

EM_Event_vod__c.RSVP_Name_AZ__c | EM_Event_vod__c.RSVP_Phone_AZ__c

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to benralizumab or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, rash) have occurred after administration of FASENRA. These reactions generally occur within hours of administration, but in some instances have a delayed onset (ie, days). Discontinue in the event of a hypersensitivity reaction.

Acute Asthma Symptoms or Deteriorating Disease

FASENRA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

It is unknown if FASENRA will influence a patient's response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with FASENRA. If patients become infected while receiving FASENRA and do not respond to anti-helminth treatment, discontinue FASENRA until infection resolves.

ADVERSE REACTIONS

The most common adverse reactions (incidence 5%) include headache and pharyngitis.

Injection site reactions (eg, pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients treated with placebo.

USE IN SPECIFIC POPULATIONS

A pregnancy exposure registry monitors pregnancy outcomes in women exposed to FASENRA during pregnancy. To enroll call 1-877-311-8972 or visit www.mothertobaby.org/fasenra.

The data on pregnancy exposure from the clinical trials are insufficient to inform on drug-associated risk. Monoclonal antibodies such as benralizumab are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

INDICATION

FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.

- FASENRA is not indicated for treatment of other eosinophilic conditions
- FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus

Please read accompanying full Prescribing Information, including Patient Information.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

AstraZeneca is committed to conducting business with the highest standards of integrity and professionalism. If you have any comments that could improve the delivery of our promotional education programs, please contact AstraZeneca at 1-800-236-9933.